Mode
Text Size
Log in / Sign up
N/A N=700 Randomized Treatment

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Cervical Cancer

Enrolled (actual)
700
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Radical Hysterectomy + pelvic lymph node dissection (Procedure); Simple hysterectomy + pelvic lymph node dissection (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Canadian Cancer Trials Group
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Pelvic Recurrence Rate at 3 Years
2.17; 2.52
SECONDARY
Pelvic Relapse-free Survival
97.5; 97.8
SECONDARY
Extra-pelvic Relapse-free Survival
99.7; 98.1
SECONDARY
Relapse-free Survival
97.8; 96.3
SECONDARY
Overall Survival
99.4; 99.1

Summary

The reason this study is being done is to see if a simple hysterectomy is as good as a radical hysterectomy in preventing cancer of the cervix from returning, and whether, because less tissue surrounding the uterus is removed during surgery, there are fewer side-effects after the surgery and in the long-term.

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed adenocarcinoma, squamous, or adenosquamous cancer of the cervix. Diagnosis has been made by LEEP, cone or cervical biopsy and has been reviewed and confirmed by the local reference gynecological pathologist.
  • Patient has been classified as low-risk early-stage cervical cancer. These patients include:
  • FIGO Stage IA2 [FIGO Annual Report, 2009], defined as:

o evidence of disease by microscopy;

  • for patients who underwent a LEEP or cone:
  • histologic evidence of depth of stromal invasion > 3.0 and ≤ 5.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen NB: the maximum depth of stromal invasion must be ≤ 10 mm.
  • histologic evidence of lateral extension that is ≤ 7.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen; and
  • negative margins (patients with positive margins are considered IB1, see below)
  • for patients who underwent a cervical biopsy only:
  • radiologic evidence of less than 50% stromal invasion based on pelvic MRI
  • FIGO Stage IB1 [FIGO Annual Report, 2009] with favorable (low risk) features, defined as:
  • measured stromal invasion and lateral extension that meet the criteria for IA2 (see above) but with positive margins;
  • evidence of disease by clinical exam; lesion must clinically measure ≤ 20 mm
  • evidence of disease by microscopy;
  • for patients who underwent a LEEP or cone:
  • histologic evidence of depth of stromal invasion between 5.1-10 mm and/or lateral extension between 7.1-20.0 mm based on the local reference pathologist's measurement of the LEEP or cone specimen
  • for patients who underwent a cervical biopsy only:
  • radiologic evidence of less than 50% stromal invasion based on pelvic MRI
  • lateral extension ≤ 20 mm based on clinical exam or radiologic imaging.

In addition to above criteria on maximal stromal invasion of ≤ 10 mm, the lesion must be no larger than 20 mm in any dimension by any assessment method (MRI, clinical or histological exam). To ensure patients meet this criterion, investigators may need to sum the lesion measurements from biopsy and other methods that evaluate it in the same plane.

Patients are eligible irrespective of the presence or absence of lymph-vascular space involvement (LVSI).

  • Physical examination, recto-vaginal examination and visualization of the cervix by speculum or colposcopic examination have been done after the initial diagnostic procedure (LEEP, cone or biopsy) and prior to randomization.
  • Chest x-ray or CT scan of chest AND pelvic MRI* done after initial diagnostic procedure (LEEP, cone or biopsy) and prior to randomization.

The CT should be a 16 slice (or higher) helical scanner. Oral and intravenous contrasts are preferred (unless there is a contraindication to the use of contrast) with scan obtained in the portal phase at a slice thickness of 5mm or lower Pelvic MRI should be performed on a 1.5 or 3 Tesla magnet with pelvic phased-array coils. The MR pulse sequences will consist of T1 gradient echo in the axial plane at 5 mm slice thickness and fast spin echo in the axial, sagittal, and coronal planes at 4 mm slice thickness. The short axis (perpendicular to the tumour's long axis) with a 3 mm slice thickness is required in the best plane to show the maximum thickness of stromal invasion. Use of an anti-peristaltic agent is mandatory while intravenous use of gadolinium or diffusion-weighted imaging (DWI) is optional.

  • Note: pelvic MRI is optional if the patient has stage IA2 disease and underwent a LEEP or cone.
  • After consideration of a patient's medical history, physical examination and laboratory testing, patients must be suitable candidates for surgery as defined by the attending physician / investigator.
  • Patients must have no desire to preserve fertility.
  • Patients fluent in English or French must be willing to complete the Quality of Life Questionnaire. The baseline assessments must be completed within 6 weeks pri
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01658930). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search